• ERAD-Engaging Chimeras: Targeted Degradation of TM Proteins

  2026-05-27

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule platform that selectively induces degradation of transmembrane proteins by hijacking the endoplasmic reticulum-associated degradation pathway. This innovation addresses key limitations of existing targeted protein degradation approaches, offering a new strategy for membrane protein modulation in disease and signaling research.

• Hydrocortisone: Translational Leverage in Inflammation & Neu

  2026-05-27

  This thought-leadership article explores how hydrocortisone, a benchmark glucocorticoid hormone, enables advanced translational research across inflammation models, stress response mechanisms, and neuroprotection. Integrating mechanistic insights and strategic protocol guidance, it provides a roadmap for researchers aiming to bridge preclinical innovation with clinical relevance, leveraging the unique properties and validated performance of APExBIO’s Hydrocortisone (SKU B1951).

• TRIM21 Drives ERK1/2-Mediated Proliferation and Drug Resista

  2026-05-26

  This study identifies TRIM21 as a key regulator of cell proliferation and drug resistance in pituitary adenomas through ERK1/2 ubiquitination and phosphorylation. Notably, the work highlights the potential of HDAC inhibitors like Quisinostat to downregulate TRIM21, offering a promising therapeutic approach for dopamine agonist-resistant pituitary tumors.

• Caspase-8 Activation Drives Enhanced Apoptosis in Hypertherm

  2026-05-26

  This study uncovers how combining hyperthermia with cisplatin therapy induces caspase-8 accumulation and activation, leading to greater apoptosis and pyroptosis in cancer cells. The work clarifies the molecular mechanism of synergy, providing an actionable framework for researchers investigating programmed cell death and caspase signaling in therapeutic contexts.

• Polybrene (Hexadimethrine Bromide) 10 mg/mL: Mechanism & Ben

  2026-05-25

  Polybrene (Hexadimethrine Bromide) 10 mg/mL is a validated reagent used to enhance viral gene transduction and lipid-mediated DNA transfection. By neutralizing electrostatic repulsion, it increases viral and DNA uptake efficiency in diverse cell lines. The APExBIO K2701 formulation provides stable, sterile delivery for advanced gene delivery workflows.

• Optimizing Cancer and Cell Viability Assays with IWP-2 (SKU

  2026-05-25

  This article delivers practical, evidence-based strategies for deploying IWP-2 (SKU A3512) as a Wnt production inhibitor in cell viability, proliferation, and apoptosis assays. Drawing on peer-reviewed research and validated protocols, it guides biomedical scientists through experimental design, troubleshooting, and vendor selection, ensuring data reliability and workflow efficiency.

• Network Pharmacology Reveals Apigenin’s Neuroprotective Mech

  2026-05-24

  This article examines a recent network medicine study that systematically identified Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) as a key neuroprotective flavonoid for Alzheimer’s disease. Integrating computational and experimental evidence, the research highlights Apigenin’s modulation of apoptosis, inflammation, and microglial polarization, offering actionable insights for neurodegeneration models.

• CX-4945 (Silmitasertib): CK2 Inhibition for Cancer & Virolog

  2026-05-23

  CX-4945 (Silmitasertib) stands at the forefront of translational research by enabling precise CK2 inhibition for both oncology and emerging antiviral workflows. This guide details practical assay design, troubleshooting, and cross-domain innovation—empowering researchers to leverage APExBIO’s trusted quality for robust, reproducible results.

• LNP-Stabilized Emulsions Enable Targeted mRNA Delivery and P

  2026-05-22

  Zhou et al. developed a lipid nanoparticle-stabilized emulsion (LSE) system that achieves spatiotemporal control over mRNA delivery, biasing antigen expression toward antigen-presenting cells and enhancing T cell responses. This innovation addresses longstanding challenges in mRNA vaccine efficacy by reducing off-target transfection and improving immune activation profiles.

• Optimizing Cell Assays with EZ Cap™ Firefly Luciferase mRNA

  2026-05-22

  This article explores scenario-driven strategies for enhancing cell viability, proliferation, and gene regulation assays using EZ Cap™ Firefly Luciferase mRNA (SKU R1018). Grounded in recent literature and practical workflow considerations, it highlights how Cap 1 structure and poly(A) tail engineering deliver reproducible, sensitive bioluminescence readouts for demanding experimental setups.

• Elobixibat Hydrate: Applied Workflows for IBAT Inhibition Re

  2026-05-21

  Elobixibat hydrate delivers precision control over bile acid signaling for translational studies in metabolism and gastrointestinal function. This guide details optimized protocols, advanced troubleshooting, and actionable insights for researchers pursuing chronic idiopathic constipation and metabolic modulation in type 2 diabetes models.

• LLY-507: SMYD2 Inhibitor Workflows for Cancer and Fibrosis M

  2026-05-21

  LLY-507, a highly selective SMYD2 inhibitor, empowers cancer and fibrosis researchers to interrogate lysine methylation pathways with unprecedented precision. This guide delivers actionable workflows, troubleshooting insights, and translational perspectives to maximize experimental success using LLY507 from APExBIO.

• TAI-1: A Potent Hec1 Inhibitor Transforming Cancer Workflows

  2026-05-20

  TAI-1 sets a new benchmark for Hec1 inhibition, enabling precise disruption of mitotic processes in cancer cells with unmatched potency. This article decodes its applied workflows, practical troubleshooting, and unique role in advanced cancer models—including RB1-deficient retinal organoids.

• Protein A/G Magnetic Beads: Precision Tools for Cancer Stem

  2026-05-20

  Explore how Protein A/G Magnetic Beads empower high-specificity antibody purification and protein interaction analysis in cancer stem cell research. This article offers a unique perspective on optimizing stemness and chemoresistance studies, building on the latest scientific breakthroughs.

• Actinomycin D: Strategic Insights for Translational Oncology

  2026-05-19

  This thought-leadership article explores how Actinomycin D (ActD) transforms translational cancer research, with a spotlight on its mechanistic role in regulating RNA synthesis, apoptosis, and the DNA damage response. Integrating new findings on hypoxia-driven feedback loops in pancreatic cancer, we provide actionable guidance for researchers targeting complex transcriptional networks. The discussion further differentiates APExBIO's ActD offering through evidence-backed protocol recommendations and strategic positioning beyond traditional use cases.

497 records 13/34 page Previous Next First page 上5页 1112131415 下5页 Last page